ClinicalTrials.gg
RecruitingNCT05386615Updated Apr 30, 2025

Post-Exablate Pregnancy Outcomes Registry Study: Exablate Treatment of Symptomatic Uterine Fibroids

An observational study in Uterine Fibroid, sponsored by InSightec. Recruiting at 6 sites in 2 countries. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-04-30.

Sponsored by InSightec · Observational

From the registry’s dates

  • Started Feb 2016; still recruiting 10 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Other
Enrollment
200
Ages
18 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 10 studies in Leiomyoma by InSightec — 1 open to participants now, 1 under way, none of them phase 3. Leiomyoma · InSightec.

Started
2016
the only one that year
Observational
Only one
of the 10
Registered
10th of 10
by date

Among the 10 studies in Leiomyoma by InSightec, this one is the only one that started in 2016, is the only observational one, and was the 10th registered.

Leiomyoma

438 studies on the registry are indexed under Leiomyoma; 74 are open to participants now.

Browse Leiomyoma studies →

Open to participants now

1 of the 10 studies in Leiomyoma by InSightec is open now, in 2 countries.

By country, each count listing its studies:

Who these studies take

Of the 44 Leiomyoma studies recruiting now, 22 (50%) set no upper age limit and 21 (48%) stop at 75 or younger; 4 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 50 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Leiomyoma by InSightec, or all of them as a file.
02

Study summary

The goal of this Registry Study is to capture clinical pregnancy outcomes and fibroid treatment background data for any subject post-Exablate treatment for their symptomatic fibroids.

Read the detailed description

This is an observational study only for all consented subjects who undergo an Exablate treatment. The Exablate procedure is a commercial treatment. The objective of this registry is to collect data about the effect of Exablate treatment on potential pregnancy occurrences in this population for two years post-treatment for purposes of labeling updates and overall safety data collection.

03

Conditions studied

  • Uterine Fibroid

Browse trials for

Keywords

  • Uterine Fibroids
  • Exablate
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

pre- and peri- menopausal women with Uterine Fibroids

Eligibility criteria

Inclusion Criteria: - - Eligibility is as per the symptomatic fibroids device indication. - All registry-consented patients following the treatment of their fibroid(s) with the Exablate system. Exclusion Criteria: -

05

Study design

Observational model
Other
Time perspective
Other
Enrollment
200 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes

Groups and cohorts

  • Exablate

    Observational study of Exablate treatment.

    Device: Body System - Functional

Interventions

  • DeviceBody System - Functional

    MR-Guided Focused Ultrasound

06

What researchers measure

Primary outcomes

  1. Occurrence of adverse events

    All adverse events and/or serious adverse events will be documented and reported according to protocol.

    Time frame: Through study completion, an average of 2 years.

07

Study locations

5 of 6 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2016 (actual). Primary completion is estimated for Dec 2026, 130 months after the start.

Of 45 observational studies under Leiomyoma, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 99. This study's planned 130 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2022
First posted
May 23, 2022
StartActual
Feb 16, 2016
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Apr 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05386615
Lead sponsor
InSightec
Responsible party
Sponsor
First posted
May 23, 2022
Start date
Feb 16, 2016
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Apr 30, 2025

Study contacts

Nadir Alikacem
Contact
nadira@insightec.com
+12146302000

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion